FFRangio System vs EchoNext
AI Verdict
Choose FFRangio System if…
Choose the FFRangio System if your cardiology department requires real-time, wire-free, and drug-free fractional flow reserve (FFR) guidance during percutaneous coronary intervention (PCI) procedures. This tool is ideal for optimizing and confirming PCI decisions by providing accurate multi-vessel FFR results and advanced insights directly within the cath lab, eliminating the need for invasive pressure wires and associated drugs.
View FFRangio System →Choose EchoNext if…
Choose EchoNext if your practice or hospital aims to non-invasively screen a broad patient population for hidden structural heart disease using standard ECGs. This AI-powered tool is particularly well-suited for early detection of conditions like heart failure, valve disease, and pulmonary hypertension, offering a cost-effective and accessible diagnostic support solution for various clinical settings, from major hospitals to community practices.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | FFRangio System | EchoNext |
|---|---|---|
| Pricing | Contact for pricing | Starts at $600/month |
| Deployment | On-premise (integrates with cath lab equipment and C-arm angiography systems) | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
FFRangio SystemFFRangio System emphasizes an 'intuitive user interface' and 'seamless integration with cath lab boom and PACS,' aiming to streamline procedural workflow and simplify the operator experience. EchoNext is available through a clinical decision support platform, which suggests ease of access, but its direct user interface experience isn't detailed as extensively as FFRangio's.
Clinical Value
EchoNextEchoNext has demonstrated higher accuracy (77%) in identifying structural heart problems from ECGs compared to cardiologists (64%), even when cardiologists were assisted by AI (69%). It also has FDA clearance for six indications, including heart failure, valve disease, and pulmonary hypertension. While FFRangio shows high concordance with invasive FFR wires (93% diagnostic accuracy) and comparable one-year major adverse cardiac event rates, its impact is within an existing invasive procedure.
Pricing & Value
EchoNextEchoNext offers transparent tiered pricing starting at $600/month, making it easier for potential customers to understand costs. FFRangio's pricing is 'contact for pricing,' which lacks transparency. Additionally, EchoNext's ability to screen for multiple conditions from a routine ECG offers broad value as an early detection tool.
Enterprise Readiness
EchoNextEchoNext is available through the OpenEvidence clinical decision support platform, which is used by over 650,000 U.S. physicians, indicating a strong existing distribution and integration network. It also explicitly states it's designed for broad access, from major hospitals to community practices. FFRangio is an on-premise solution integrating with cath lab equipment, which suggests a more specialized and potentially complex deployment.
Innovation
EchoNextEchoNext is described as the 'world's first FDA-approved AI detection tool' to analyze standard ECGs for hidden structural heart disease, representing a new paradigm for early detection. FFRangio, while innovative in providing wire-free FFR guidance, operates within the existing framework of coronary angiography.
Support & Docs
TieBoth tools provide limited public information regarding their support and documentation. FFRangio offers an 'Instructions For Use (IFU)' document upon request, while EchoNext's documentation is not explicitly detailed on public sources. Without more specific information on the breadth and accessibility of support resources, it's difficult to determine a clear winner.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | FFRangio System | EchoNext |
|---|---|---|
| Tool Name | FFRangio System | EchoNext |
| Company | CathWorks | Pathway Labs |
| Description | The CathWorks FFRangio System delivers wire-free and drug-free 3D FFR guidance, providing accurate multi-vessel FFR results and advanced insights to quickly optimize and confirm PCI decisions for patients with coronary artery disease. | EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Features (Primary Focus) | Real-time FFRangio values, simulated pullback curve, lesion impact assessment, integrated sizing tool, AI-aided angiogram analysis, wire-free and drug-free. | AI-powered ECG analysis, detection of hidden structural heart disease (heart failure, valve disease, pulmonary hypertension), utilizes standard 12-lead ECGs. |
Videos
Demos, reviews, and walkthroughs featuring FFRangio System and EchoNext.
More Comparisons
More matchups featuring FFRangio System or EchoNext
Backers
Who funded each tool's parent company.